Daily Archives: July 23, 2021

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial

Posted on July 23, 2021 by Gastroenterology Journal

Increased de novo lipogenesis creates excess intrahepatic fat and lipotoxins, propagating liver damage in nonalcoholic steatohepatitis (NASH). TVB-2640, a fatty acid synthase (FASN) inhibitor, was designed to reduce excess liver fat and directly inhibi… Continue reading →

Posted in News | Comments Off on TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial

Unlocking the mind might be critical in management of eosinophilic esophagitis: Expanding beyond drugs, dilation, and diet

Posted on July 23, 2021 by Gastroenterology Journal
Posted in News | Comments Off on Unlocking the mind might be critical in management of eosinophilic esophagitis: Expanding beyond drugs, dilation, and diet